Under construction – not a live service

Skip to content

Frontlight Research

Institution

Royal Marsden Hospital

London, United KingdomWebsite

Also known as: RM

214running trials
78closed trials
21,641publications (OpenAlex)

Running trials

Not yet recruiting
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
NCT07675733· Royal Marsden NHS Foundation Trust· Source
Recruiting
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
NCT07649525· Phase 3· University of Leeds· Source
Recruiting
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817· Phase 2· Boehringer Ingelheim· Source
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
Patient and Provider Perspectives on Genetic Risk Profiling
NCT07741929· Royal Marsden NHS Foundation Trust· Source
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· BioNTech SE· Source
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· Phase 2/3· Cancer Research UK· Source
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise
NCT07243834· Royal Marsden NHS Foundation Trust· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691· Janssen Research & Development, LLC· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Cancer Research UK· Source
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· Phase 3· Amgen· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842· Phase 1/2· BioNTech SE· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488· Phase 1/2· Celgene· Source
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Pfizer· Source
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· Phase 1/2· BioNTech SE· Source
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· Phase 1/2· BioNTech SE· Source
Recruiting
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
NCT06976892· Phase 1· Institute of Cancer Research, United Kingdom· Source
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· Phase 1· Amgen· Source
Active, not recruiting
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457· Pierre Fabre Ltd· Source
Recruiting
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).
NCT06636526· Institute of Cancer Research, United Kingdom· Source
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272· Phase 1/2· Merck Sharp & Dohme LLC· Source

Showing 50 of 214.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer38 recruiting
Childhood cancers27 recruiting
Colorectal cancer26 recruiting
Prostate cancer22 recruiting
Gastric and oesophageal cancer17 recruiting
Ovarian cancer16 recruiting
Pancreatic cancer15 recruiting
Head and neck cancer11 recruiting
Melanoma10 recruiting
Sarcoma10 recruiting
Bladder cancer9 recruiting
Metastatic breast cancer8 recruiting
Multiple myeloma8 recruiting
Liver and biliary tract cancer7 recruiting
Endometrial cancer6 recruiting
Kidney cancer6 recruiting
Neuroblastoma5 recruiting
Acute lymphoblastic leukaemia3 recruiting
Glioblastoma3 recruiting
Hodgkin lymphoma3 recruiting
Thyroid cancer3 recruiting
Triple-negative breast cancer3 recruiting
Acute myeloid leukaemia2 recruiting
Cervical cancer2 recruiting
Chronic lymphocytic leukaemia2 recruiting
Myelodysplastic syndromes2 recruiting
Amyloidosis1 recruiting
Chronic myeloid leukaemia1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Follicular lymphoma1 recruiting
Mantle cell lymphoma1 recruiting
Mesothelioma1 recruiting
Myeloproliferative neoplasms1 recruiting

Closed trials

Completed
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
NCT06615921· Takeda· Source
Terminated
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
NCT06523803· Phase 1· Zymeworks BC Inc.· Source
Withdrawn
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
NCT06498518· Phase 2· Karen Carty· Source
Completed
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793· Phase 3· Boehringer Ingelheim· Source
Completed
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05848011· Phase 2· MacroGenics· Source
Completed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· Phase 2· BeiGene· Source
Completed
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
NCT05441501· Phase 1· Janssen Research & Development, LLC· Source
Withdrawn
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
NCT04315246· Phase 1/2· Y-mAbs Therapeutics· Source
Terminated
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
NCT05358808· Phase 2· TC Biopharm· Source
Completed
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
NCT05546905· Pierre Fabre Medicament· Source
Terminated
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· Phase 2/3· PTC Therapeutics· Source
Completed
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
NCT05198934· Phase 3· Amgen· Source
Completed
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
NCT05249426· Phase 1· Boehringer Ingelheim· Source
Completed
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
NCT05323656· Phase 2· Calliditas Therapeutics Suisse SA· Source
Completed
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT05218499· Phase 2/3· Boehringer Ingelheim· Source
Completed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127· Phase 2/3· ALX Oncology Inc.· Source
Terminated
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
NCT05228015· Phase 1· Ikena Oncology· Source
Completed
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
NCT04907851· Phase 2· Redx Pharma Ltd· Source
Completed
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
NCT04907539· Phase 2· Redx Pharma Ltd· Source
Completed
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
NCT04830592· Phase 1· Akamis Bio· Source
Completed
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Completed
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
NCT04702737· Phase 1· Amgen· Source
Completed
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
NCT04855929· Phase 1· Anaveon AG· Source
Completed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· Phase 3· Hoffmann-La Roche· Source
Completed
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
NCT04776148· Phase 3· Merck Sharp & Dohme LLC· Source
Terminated
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT03850795· Phase 3· Hinova Pharmaceuticals USA, Inc.· Source
Completed
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831· Phase 2· Daiichi Sankyo· Source
Terminated
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT04501614· Phase 1/2· Takeda· Source
Terminated
A Study of SGN-STNV in Advanced Solid Tumors
NCT04665921· Phase 1· Seagen Inc.· Source
Completed
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
NCT04543617· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT04322539· Phase 3· Hutchison Medipharma Limited· Source
Completed
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
NCT04338269· Phase 3· Hoffmann-La Roche· Source
Completed
Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
NCT04566614· Royal Marsden NHS Foundation Trust· Source
Completed
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
NCT04303780· Phase 3· Amgen· Source
Terminated
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
NCT04254107· Phase 1· Seagen Inc.· Source
Completed
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT04382664· Phase 2· Ultimovacs ASA· Source
Completed
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
NCT04199104· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
NCT04068181· Phase 2· Amgen· Source
Completed
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
NCT04145349· Phase 1/2· Eli Lilly and Company· Source
Terminated
NOLA (NeuWave Observational Liver Ablation) Registry
NCT04107766· Ethicon, Inc.· Source
Completed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502· Phase 3· Takeda· Source
Completed
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
NCT05993299· Phase 2· USWM, LLC (dba US WorldMeds)· Source
Completed
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT06703346· Phase 2· USWM CT, LLC· Source
Terminated
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
NCT04382898· Phase 1/2· BioNTech SE· Source
Completed
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
NCT04014075· Phase 2· Daiichi Sankyo· Source
Terminated
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704· Phase 2· Seagen Inc.· Source
Completed
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 78.

Registry name variants (85)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Royal Marsden Hospital
London, SW3 6JJ
64 trials
Royal Marsden Hospital
Sutton, Surrey SM2 5PT
64 trials
The Royal Marsden Hospital
London, SW3 6JJ
29 trials
Royal Marsden Hospital (Sutton)
Sutton, SM2 5PT
23 trials
The Royal Marsden Hospital
Sutton, SM2 5PT
23 trials
Royal Marsden Hospital (Sutton)
London, SM2 5PT
16 trials
Royal Marsden Hospital (Chelsea)
London, Kensington and Chelsea SW3 6JJ
15 trials
Royal Marsden Hospital - London
London, SW3 6JJ
13 trials
The Royal Marsden Hospital, Chelsea
London, SW3 6JJ
10 trials
The Royal Marsden Hospital, Sutton
Sutton, SM2 5PT
9 trials
Royal Marsden Hospital
Chelsea, England SW36JJ
5 trials
Royal Marsden Hospital - Fulham
London, SW3 6JJ
5 trials
Royal Marsden Hospital - Surrey
Sutton, Surrey SM2 5PT
5 trials
The Royal Marsden Hospital (Surrey)
Sutton, Queensland SM2 5PT
5 trials
Royal Marsden Hospital
Surrey, SM2 5PT
2 trials
- NCT05438043A Study of Daratumumab
- NCT03277105A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Royal Marsden Hospital - Surrey
Surrey Quays, SM2 5PT
2 trials
- NCT04501614A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
  Contact: Emma (Xiaoning) Cai
The Royal Marsden Hospital - Drug Development Unit
Sutton, SM2 5PT
2 trials
- NCT066302605G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
  Contact: Juanita Lopez, MD, PhD
- NCT066322365G-EMERALD: Amivantamab in Malignant Brain Tumours
The Royal Marsden Hospital- London
London, 6JJ
2 trials
- NCT05323656A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
- NCT04675333Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Cancer Genetics Unit, Royal Marsden Hospital
London, Sutton, Surrey SM2 5PT
1 trial
- NCT05097274The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.
  Contact: Rosalind Eeles, MA; PhD; FRCP; FRCR; FMedSci
Cancer Genetics Unit, Royal Marsden Hospital
Sutton, Surrey SM2 5PT
1 trial
- NCT00261456The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
Head and Neck Unit, Royal Marsden Hospital
London, SW3 6JJ
1 trial
- NCT05808920The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
  Contact: Vishak Muraleedharan Shylaja
Pharmacy: Royal Marsden Hospital
Sutton, Surrey SM2 5PT
1 trial
- NCT05208762A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Royal Marsden Hospital
Kingston upon Thames, KT2 7QB
1 trial
- NCT03782207A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Royal Marsden Hospital
Skerray, SM2 5PT
1 trial
- NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre (Site 2807)
London, England SW10 9NH
1 trial
- NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre (Site 4002)
London, England SW3 6JJ
1 trial
- NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Royal Marsden Hospital - Chelsea, London
London, SW3 6JJ
1 trial
- NCT02194842Phase III Radium 223 mCRPC-PEACE III
ROYAL MARSDEN HOSPITAL (CHELSEA)-Lung Unit (Site 2075)
London, Kensington and Chelsea SW3 6JJ
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 0283)
London, London, City of SW3 6JJ
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Royal Marsden Hospital - Chelsea (Site #0505)
London, SW3 6JJ
1 trial
- NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
  Contact: Principal Investigator
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 0701)
London, London, City of SW3 6JJ
1 trial
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 1201)
London, London, City of SW3 6JJ
1 trial
- NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 1403)
London, London, City of SW3 6JJ
1 trial
- NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 1804)
London, London, City of SW3 6JJ
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 2606)
London, Kensington and Chelsea SW3 6JJ
1 trial
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 2801)
London, London, City of SW3 6JJ
1 trial
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 2806)
London, London, City of SW3 6JJ
1 trial
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 3201)
London, London, City of SW3 6JJ
1 trial
- NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 4006)
London, London, City of SW3 6JJ
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
Royal Marsden Hospital Department of Medicine
London, SW3 6JJ
1 trial
- NCT03869892Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
Royal Marsden Hospital Department of Medicine
Sutton, SM2 5PT
1 trial
- NCT03869892Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
Royal Marsden Hospital;Dept of Med-Onc
London, SW3 6JJ
1 trial
- NCT04929223A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Royal Marsden Hospital - Drug Development Unit
Sutton, London SM2 5NG
1 trial
- NCT06976892Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
  Contact: Prof Udai Banerji, MBBS MD DNB PhD FRCP
Royal Marsden Hospital (Fulham Road)
London
1 trial
- NCT03762018BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Royal Marsden Hospital - Fulham Road London (Site 0613)
London, London, City of SW3 6JJ
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Royal Marsden Hospital - Fulham Road London (Site 1609)
London, London, City of SW3 6JJ
1 trial
- NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Royal Marsden Hospital;Institute of Cancer Research
Sutton, SM2 5PT
1 trial
- NCT02500407A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Royal Marsden Hospital - Institute of Cancer Research - Chelsea
London, SM2 7LN
1 trial
- NCT04382664UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Royal Marsden Hospital - London, Department of Medical Oncology
London
1 trial
- NCT05501886Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Royal Marsden Hospital (Site 0402)
Fulham, England SW3 6JJ
1 trial
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
Royal Marsden Hospital (Site 0457)
Sutton, London, City of SM2 5PT
1 trial
- NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Royal Marsden Hospital (Site 0526)
Sutton, England SM2 5PT
1 trial
- NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Royal Marsden Hospital (Site 0536)
London, London, City of SW3 6JJ
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Royal Marsden Hospital. (Site 0901)
Sutton, Surrey SM2 5PT
1 trial
- NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Royal Marsden Hospital (Site 0902)
London, London, City of SW3 6JJ
1 trial
- NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Royal Marsden Hospital (Site 1510)
Sutton, Surrey SM2 5PT
1 trial
- NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Royal Marsden Hospital (Site 2904)
Sutton, London, City of SM2 5PT
1 trial
- NCT04199104A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Royal Marsden Hospital (Site 3347)
Sutton, SM2 5PT
1 trial
- NCT06941272A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
  Contact: Study Coordinator
Royal Marsden Hospital - site: Chelsea, London
London, SW3 6JJ
1 trial
- NCT04498767Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
  Contact: EORTC HQ
Royal Marsden Hospital - site: Sutton, Surrey
Sutton, SM2 5PT
1 trial
- NCT02205047Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
Royal Marsden Hospital - Surrey
London, SW7 3RP
1 trial
- NCT05152147A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Royal Marsden Hospital - Sutton
Surrey Quays, SM2 5PT
1 trial
- NCT06112314IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Royal Marsden Hospital (Sutton)-Drug Development Unit (Site 1347)
Sutton, Surrey SM2 5PT
1 trial
- NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
  Contact: Study Coordinator
Royal Marsden Hospital (Sutton)-Gynaecology Unit (Site 0696)
London, Surrey SM3 5PT
1 trial
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Royal Marsden Hospital (Sutton)-Gynaecology Unit (Site 2801)
Sutton, England SM2 5PT
1 trial
- NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Royal Marsden Hospital (Sutton)-Gynaecology Unit (Site 4010)
London, Sutton SW3 6JJ
1 trial
- NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Royal Marsden Hospital (Sutton) (Site 0281)
Sutton, Surrey SM2 5PT
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Royal Marsden Hospital (Sutton) (Site 0741)
London, Surrey SM3 5PT
1 trial
- NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  Contact: Study Coordinator
Royal Marsden Hospital (Sutton) (Site 0800)
London, Surrey SM3 5PT
1 trial
- NCT03797326Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Royal Marsden Hospital (Sutton) (Site 0922)
Sutton, London, City of SM2 5PT
1 trial
- NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  Contact: Study Coordinator
Royal Marsden Hospital (Sutton) (Site 1407)
London, Surrey SM3 5PT
1 trial
- NCT04380636Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Royal Marsden Hospital (Sutton) (Site 1409)
London, Surrey SM3 5PT
1 trial
- NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Royal Marsden Hospital (Sutton) (Site 2076)
London, London, City of SW3 6JJ
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
Royal Marsden Hospital (Sutton) (Site 2605)
Sutton, Surrey SM2 5PT
1 trial
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Royal Marsden Hospital (Sutton) (Site 2802)
Sutton, London, City of SM2 5PT
1 trial
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
Royal Marsden Hospital (Sutton) (Site 4005)
London, Surrey SM3 5PT
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
The Royal Marsden Hospital
Chelsea
1 trial
- NCT05376891Met Non Small Cell Cancer Registry (MOMENT)
  Contact: Sanjay Popat (principal investigator)
The Royal Marsden Hospital Chelsea
Chelsea
1 trial
- NCT04550104A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
  Contact: Merina Ahmed (principal investigator)
The Royal Marsden Hospital - Chelsea Site
London, SW3 6JJ
1 trial
- NCT05253651A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
The Royal Marsden Hospital, Fulham
London, SW3 6JJ
1 trial
- NCT03452137A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The Royal Marsden Hospital - Neuro-Oncology Unit
Sutton, SM2 5PT
1 trial
- NCT066302605G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
  Contact: Liam Welsh, MD
The Royal Marsden Hospitals
London
1 trial
- NCT05604963Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
  Contact: Vinidh Paleri (principal investigator)
The Royal Marsden Hospital (Surrey)
Surrey Quays, SM25PT
1 trial
- NCT04907539A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
The Royal Marsden Hospital - Surrey
London, 5PT
1 trial
- NCT04675333Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
The Royal Marsden Hospital (Sutton and Chelsea)
London, SM2 5PT
1 trial
- NCT07741929Patient and Provider Perspectives on Genetic Risk Profiling
  Contact: Tarryn Shaw, MSc Genetic Counselling

Conditions

Diseases this institution publishes on or runs trials for.

Prostate cancer66 works · 45 trials
Sarcoma56 works · 20 trials
Metastatic breast cancer27 works · 9 trials
Kidney cancer26 works · 9 trials
Multiple myeloma22 works · 19 trials
Head and neck cancer16 works · 23 trials
Childhood cancers10 works · 46 trials
Neuroblastoma10 works · 7 trials
Mesothelioma5 works · 5 trials

Institution data: ROR 034vb5t35 (CC0-1.0)Updated 10 Nov 2026

Report an error